[go: up one dir, main page]

MX2017016862A - Composicion farmaceutica estable para administracion oral. - Google Patents

Composicion farmaceutica estable para administracion oral.

Info

Publication number
MX2017016862A
MX2017016862A MX2017016862A MX2017016862A MX2017016862A MX 2017016862 A MX2017016862 A MX 2017016862A MX 2017016862 A MX2017016862 A MX 2017016862A MX 2017016862 A MX2017016862 A MX 2017016862A MX 2017016862 A MX2017016862 A MX 2017016862A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
oral administration
stable pharmaceutical
compound
pharmaceutically acceptable
Prior art date
Application number
MX2017016862A
Other languages
English (en)
Other versions
MX378947B (es
Inventor
MIYAZAKI Mazakazu
Ishiba Ryohei
TAKAISHI Yuki
UEJO Fumiaki
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57686183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017016862(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2017016862A publication Critical patent/MX2017016862A/es
Publication of MX378947B publication Critical patent/MX378947B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona una composición farmacéutica estable para administración oral que comprende 6-etil-3-({3-metoxi-4-[4-(4-meti lpiperazin-1-il)piperidin-1-il]fenil}amino)-5-(tetrahidro-2H-pira n-4-ilamino)pirazin-2-carboxamida (de aquí en adelante referida como compuesto A) o una sal farmacéuticamente aceptable de la misma, en donde se inhibe la generación de sustancias relacionadas durante el almacenamiento. En la composición farmacéutica estable para administración oral, la proporción de cristales de compuesto A o una sal farmacéuticamente aceptable de la misma es 60% o más con respecto a la cantidad total del Compuesto A o una sal farmacéuticamente aceptable del mismo.
MX2017016862A 2015-07-03 2016-07-01 Composición farmacéutica estable para administración oral. MX378947B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015134817 2015-07-03
PCT/JP2016/069615 WO2017006855A1 (ja) 2015-07-03 2016-07-01 安定な経口投与用医薬組成物

Publications (2)

Publication Number Publication Date
MX2017016862A true MX2017016862A (es) 2018-04-24
MX378947B MX378947B (es) 2025-03-11

Family

ID=57686183

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016862A MX378947B (es) 2015-07-03 2016-07-01 Composición farmacéutica estable para administración oral.

Country Status (21)

Country Link
US (9) US10786500B2 (es)
EP (2) EP3318259B1 (es)
JP (2) JP6132294B1 (es)
KR (1) KR102685890B1 (es)
CN (1) CN107847500B (es)
CA (1) CA2989534C (es)
DK (1) DK3318259T3 (es)
ES (1) ES2940306T3 (es)
FI (1) FI3318259T3 (es)
HR (1) HRP20230253T1 (es)
HU (1) HUE061697T2 (es)
LT (1) LT3318259T (es)
MX (1) MX378947B (es)
PH (1) PH12017502252B1 (es)
PL (1) PL3318259T3 (es)
PT (1) PT3318259T (es)
RS (1) RS64070B1 (es)
SI (1) SI3318259T1 (es)
SM (1) SMT202300074T1 (es)
TW (1) TWI756177B (es)
WO (1) WO2017006855A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3103453B1 (en) * 2014-02-04 2020-04-01 Astellas Pharma Inc. Medicinal composition comprising diamino heterocyclic carboxamide compound as active ingredient
SI3318259T1 (sl) 2015-07-03 2023-06-30 Astellas Pharma Inc. Stabilni farmacevtski sestavki za oralno dajanje
MY204603A (en) 2019-04-03 2024-09-05 Astellas Pharma Inc Pharmaceutical composition
WO2022009235A1 (en) * 2020-07-10 2022-01-13 Msn Laboratories Private Limited, R&D Center Process for the preparation of gilteritinib fumarate
EP4370506A1 (en) 2021-12-30 2024-05-22 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
WO2025240494A1 (en) 2024-05-13 2025-11-20 Lumen Bioscience, Inc. Leptin compositions and methods of making and using the same to support weight loss and/or maintenance

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2233129B1 (en) * 2007-12-28 2014-05-07 Sawai Pharmaceutical Co., Ltd. Oral cavity disintegrating tablet and method of producing the same
SI3009428T1 (en) 2009-05-08 2018-04-30 Astellas Pharma Inc. DIAMINO HETEROCYCLIC CARBOSAMIDE COMPOUNDS
HRP20191842T1 (hr) 2011-01-07 2019-12-27 Novartis Ag Formulacije imunosupresiva
EP3103453B1 (en) 2014-02-04 2020-04-01 Astellas Pharma Inc. Medicinal composition comprising diamino heterocyclic carboxamide compound as active ingredient
TW201613579A (en) 2014-06-24 2016-04-16 Astellas Pharma Inc Pharmaceutical composition for oral administration
SI3318259T1 (sl) 2015-07-03 2023-06-30 Astellas Pharma Inc. Stabilni farmacevtski sestavki za oralno dajanje
US9755832B2 (en) 2015-12-29 2017-09-05 International Business Machines Corporation Password-authenticated public key encryption and decryption

Also Published As

Publication number Publication date
PH12017502252B1 (en) 2023-10-11
US20230301992A1 (en) 2023-09-28
CN107847500B (zh) 2021-08-10
US20230277532A1 (en) 2023-09-07
PH12017502252A1 (en) 2018-05-28
US11944620B2 (en) 2024-04-02
EP4230208A1 (en) 2023-08-23
EP3318259A1 (en) 2018-05-09
WO2017006855A1 (ja) 2017-01-12
LT3318259T (lt) 2023-05-10
US20230277529A1 (en) 2023-09-07
EP3318259A4 (en) 2019-02-27
TWI756177B (zh) 2022-03-01
US20180185359A1 (en) 2018-07-05
US20230129146A1 (en) 2023-04-27
US20230277530A1 (en) 2023-09-07
TW201716069A (zh) 2017-05-16
MX378947B (es) 2025-03-11
HRP20230253T1 (hr) 2023-04-28
RU2764750C2 (ru) 2022-01-20
ES2940306T3 (es) 2023-05-05
US20230277531A1 (en) 2023-09-07
HK1248544A1 (zh) 2018-10-19
RU2018103354A (ru) 2019-08-05
US11938132B2 (en) 2024-03-26
US11938133B2 (en) 2024-03-26
CN107847500A (zh) 2018-03-27
RS64070B1 (sr) 2023-04-28
US20200383977A1 (en) 2020-12-10
JP6798400B2 (ja) 2020-12-09
US10786500B2 (en) 2020-09-29
SMT202300074T1 (it) 2023-05-12
KR102685890B1 (ko) 2024-07-19
FI3318259T3 (fi) 2023-03-20
PT3318259T (pt) 2023-03-20
JP2017119728A (ja) 2017-07-06
KR20180023914A (ko) 2018-03-07
SI3318259T1 (sl) 2023-06-30
HUE061697T2 (hu) 2023-08-28
RU2018103354A3 (es) 2019-11-28
DK3318259T3 (en) 2023-03-06
US11938130B2 (en) 2024-03-26
CA2989534C (en) 2023-08-01
EP3318259B1 (en) 2023-01-11
US11938131B2 (en) 2024-03-26
CA2989534A1 (en) 2017-01-12
PL3318259T3 (pl) 2023-05-02
US20230310422A1 (en) 2023-10-05
JPWO2017006855A1 (ja) 2017-07-13
JP6132294B1 (ja) 2017-05-24

Similar Documents

Publication Publication Date Title
MX2017016862A (es) Composicion farmaceutica estable para administracion oral.
AR088382A1 (es) Formulaciones de etanercept estabilizadas con xilitol
GT201600142A (es) Composiciones farmacéuticas que comprenden azd9291
MX386981B (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7).
PE20191043A1 (es) Composicion farmaceutica
MA37400A1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
CL2016000816A1 (es) Forma de dosificación que comprende al compuesto (s)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona, una cantidad de 90 hasta 99,9 por ciento en peso del peso total de una mezcla de almidón y lactosa como portador o excipiente, y acido esteárico como lubricante; su uso en el tratamiento de cáncer y enfermedades autoinmunes, entre otras.
AR086254A1 (es) Derivados de imidazol utiles para el tratamiento de artritis
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
AR101674A1 (es) Uso de un compuesto tricíclico que contiene nitrógeno
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
EA201690888A1 (ru) Новые гетероциклические соединения
MX394356B (es) Métodos y composiciones para tratar hiperhidrosis.
CU24330B1 (es) Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
PH12018500378B1 (en) Novel annelated phenoxyacetamides
PH12018500377A1 (en) Novel annelated benzamides
MX2020005564A (es) Sales de 4-amino-n-(1-((3-cloro-2-fluorofnil)amino)-6-metilisoquin olin-5-il)tieno[3,2-d]pirimidino-7-carboxamida, y formas cristalinas de las mismas.
PH12016500577A1 (en) Piperazine derivatives and the use thereof as medicament
MX2015003732A (es) Tratamiento de enfermedad de alzheimer leve y moderada.
MX2022005187A (es) Compuesto de ácido oxocarboxílico heterocíclico de cinco miembros y el uso médico del mismo.
PE20211454A1 (es) Derivados de imidazopiridina y su uso como medicamento
MX2022000294A (es) Composicion oral estable de ciclofosfamida.